Investor Presentaiton

(Neo)Adjuvant Darovasertib in Primary Uveal Melanoma (UM) Paradigm Shifting Opportunity to Save the Eye, Protect Vision and Save Lives Phase 2 Study of Darovasertib Monotherapy as Neoadjuvant Therapy followed by Adjuvant Therapy Targeting FPI Q3 2023 Primary Local Therapy Adjuvant 20 20 Neoadjuvant Enucleation Cohort (n~40) Brachytherapy Cohort (n~40) Treatment to Maximum Benefit up to 6 Months Primary Endpoints • Safety • Cohort 1: Eye Preservation Adjuvant Therapy + Follow-Up • Cohort 2: Decrease in Radiation Dose Secondary Endpoints Adjuvant Therapy + Follow-Up • Useful Vision (1 yr) • Relapse Free Survival (RFS) Treatment up to 6 Months • Local (1 yr) . Distal (3 yr) Neoadjuvant Proof of Concept Adjuvant Proof of Concept Three Independent Approaches for demonstrating Clinical Benefit and defining potential Approval Pathways Enucleation Cohort Save the Eye Brachytherapy Cohort Protect Vision Adjuvant Therapy Save Lives BIOSCIENCES IDEAVA

View entire presentation